LESOGABERAN
Lesogaberan is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against gamma-aminobutyric acid type B receptor subunit 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 3 | 5 | — | — | — | 8 |
| Mitral valve insufficiency | D008944 | HP_0001653 | — | — | 2 | — | — | — | 2 |
| Heartburn | D006356 | — | R12 | — | 2 | — | — | — | 2 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | — | 2 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Renal elimination | D065667 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LESOGABERAN |
| INN | lesogaberan |
| Description | Lesogaberan (AZD-3355) was an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). As a GABAB receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD.
|
| Classification | Small molecule |
| Drug class | gabamimetics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC[C@@H](F)C[PH](=O)O |
Identifiers
| PDB | — |
| CAS-ID | 344413-67-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL448343 |
| ChEBI ID | — |
| PubChem CID | 9833984 |
| DrugBank | — |
| UNII ID | 4D6Q6HGC7Z (ChemIDplus, GSRS) |
Target
Agency Approved
GABBR1
GABBR1
Organism
Homo sapiens
Gene name
GABBR1
Gene synonyms
GPRC3A
NCBI Gene ID
Protein name
gamma-aminobutyric acid type B receptor subunit 1
Protein synonyms
GABA-B receptor, R1 subunit, gamma-aminobutyric acid (GABA) B receptor, 1, seven transmembrane helix receptor
Uniprot ID
Mouse ortholog
Gabbr1 (54393)
gamma-aminobutyric acid type B receptor subunit 1 (Q9WV18)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 100 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use